Accordingly, clinical physicians should carefully make differential diagnosis between the GFPT1‐related CMS and myasthenia gravis, metabolic myopathies, or limb‐girdle muscle dystrophy (Witherick & Brady, 2018). This evidence concerns the gene GFPT1 and myasthenia gravis.